The publisher's Medical Devices sector report, “COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update' provides comprehensive information about the COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) are used to amplify and detect the specific nucleic acid sequences of SARS-CoV-2 virus at the point-of-care.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
COVID-19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) are used to amplify and detect the specific nucleic acid sequences of SARS-CoV-2 virus at the point-of-care.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
The report enables you to:- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Overview
3 Products under Development
3.1 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
3.2 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
3.3 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
3.4 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Estimated Approval Date
3.5 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
4 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products under Development by Companies
4.1 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
4.2 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
5 COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Companies and Product Overview
6 Appendix
6.1 Methodology
6.2 About the Publisher
6.3 Contact the Publisher
6.4 Disclaimer
List of Tables
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Estimated Approval Date
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) Companies - Pipeline Products by Stage of Development
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
- Glossary
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Stage of Development
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Territory
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Regulatory Path
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Pipeline Products by Estimated Approval Date
- COVID 19 Point-of-Care (POC) Nucleic Acid Amplification Tests (NAATs) - Ongoing Clinical Trials
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aegea Biotechnologies Inc
- Aegis Sciences Corp
- Alveo Technologies
- Anavasi Diagnostics
- Anitoa Systems LLC
- Antigen Discovery Inc
- Aptorum Group Ltd
- Attoplex Co Ltd
- Baebies Inc
- Bhushan J. Toley Lab
- Biocartis Group NV
- BioLayer Corporation Limited
- BiologyWorks Inc
- Biyani Biosolutions Pvt Ltd
- CAMPTON Diagnostics UG
- CardiAI Inc
- Columbia University
- Columbia University Fertility Center
- Coyote Bioscience Co Ltd
- Credo Diagnostics Biomedical Pte Ltd
- Cue Health Inc
- Curiosity Diagnostics Sp zoo
- DiaCarta Inc
- DNA Xperts Pvt Ltd
- Eurofins Scientific SE
- FemtoDx Inc
- Flambeau Diagnostics
- Fluxergy LLC
- genedrive plc
- Hangzhou FasTech Biotechnology Co Ltd
- Harvard University
- ID Genomics Inc
- Jiangsu Qitian Gene Biotechnology Co Ltd
- KogeneBiotech Co Ltd
- Lamprogen Inc
- Lucira Health Inc
- Luminex Corp
- Lynntech Inc
- Mammoth Biosciences Inc
- McMaster University
- Meridian Bioscience Inc
- Merlin Biomedical (Xiamen) Co Ltd
- Mesa Biotech Inc
- Microgem International Plc
- Midge Medica GmbH
- NDFOS Co Ltd
- OxDX Ltd
- Patanjali Pharma Pvt Ltd
- PathogenDx, Inc.
- Pepex Biomedical, Inc.
- Prenetics Ltd
- Prime Discoveries Inc
- Princeton University
- Prominex Inc
- QuikPath Pte Ltd
- RNA Disease Diagnostics Inc
- Sense Biodetection Ltd
- Sentebiolab Biotechnology
- Shenzhen Second People's Hospital
- Shimadzu Corp
- Shionogi & Co Ltd
- Tangen Biosciences Inc
- Todos Medical
- Uh-OH Labs Inc
- University of California Berkeley
- University of Illinois at Urbana-Champaign
- University of Texas Southwestern Medical Center
- Veredus Laboratories Pte Ltd
- Visby Medical Inc
- XP Diagnostics GmbH
